Status:
COMPLETED
A Phase 2 Study of the Safety and Efficacy of a Tofimilast in Adult Patients With Chronic Obstructive Pulmonary Disease
Lead Sponsor:
Pfizer
Conditions:
Pulmonary Disease, Chronic Obstructive
Eligibility:
All Genders
40-75 years
Phase:
PHASE2
Brief Summary
This an initial proof of concept, phase to study to assess the safety and efficacy of tofimilast for the chronic maintenance treatment of adults with Chronic Obstructive Pulmonary Disease
Eligibility Criteria
Inclusion
- Moderate-severe COPD (GOLD 2003 definition)
- Smoking history of at least 10 pack-years
Exclusion
- Any significant co-morbid disease, particularly cardiovascular
- Use of any maintenance therapy except short acting bronchodilators
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2005
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00219622
Start Date
May 1 2004
End Date
July 1 2005
Last Update
November 7 2012
Active Locations (40)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States, 85006
2
Pfizer Investigational Site
Riverside, California, United States, 92506
3
Pfizer Investigational Site
Clearwater, Florida, United States, 33756
4
Pfizer Investigational Site
Clearwater, Florida, United States, 33765